SCHEMBL2821619

SCHEMBL2821619

Cc1cc(-c2ccc(N)cc2)c2c(N)nn(C)c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.45
KIT P10721 2/20 0.45
BLK P51451 2/20 0.45
HTT P42858 3/20 0.42
LMNA P02545 1/20 0.40
KDM4E B2RXH2 7/20 0.40
ALDH1A1 P00352 7/20 0.40
HPGD P15428 4/20 0.40
NPSR1 Q6W5P4 2/20 0.40
PPARG P37231 1/20 0.40
STAT3 P40763 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPT P10636 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2821616 0.84 CSF1R (0.45) CSF1RKITBLKHTTKDM4E
SCHEMBL2818604 0.83 IKBKB (0.44) CSF1RKITBLKHTTLMNA
SCHEMBL2819164 0.82 CSF1R (0.40) CSF1RKITBLKHTTLMNA
SCHEMBL3442468 0.76 CSF1R (0.61) CSF1RKITBLKHTTABL1
SCHEMBL13329767 0.75 LMNA (0.53) HTTLMNAKDM4EALDH1A1HPGD
SCHEMBL2817326 0.73 KCNH2 (0.47) HTTKDM4EALDH1A1HPGDNPSR1
SCHEMBL2818613 0.73 PDE5A (0.39) CSF1RKITBLKKDM4EALDH1A1
SCHEMBL13135802 0.73 PGR (0.50) CSF1RKITBLKLMNAMAPT
SCHEMBL30585420 0.72 CASP6 (0.45) CSF1RKITBLKKDM4EMEN1
SCHEMBL30585422 0.72 PIM1 (0.38) CSF1RKITBLKHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795264-B2 Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-09-14 US claimed
EP-2032573-A1 SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME Bayer Schering Pharma Aktiengesellschaft (DE) 2009-03-11 EP claimed
US-20080064707-A1 SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-13 US claimed
WO-2007144203-A1 SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-21 WO claimed
US-7795264-B2 Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-09-14 US disclosed
US-20080064707-A1 SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-13 US disclosed
EP-1870410-A1 Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-26 EP disclosed
EP-1867648-A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064707-A1 SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK CSF1R 629/4885KIT 29/4885BLK 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.